Strategies for tumor immune escape

Drugs of Today

Volumn 39, Issue 9, 2003, Pages 701-724

  Piemonti, Lorenzo ^a,b   Zerbi, Alessandro ^a   Di Carlo, Valerio ^a,b  

^a Laboratory of Experimental Surgery   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CONNEXIN 37; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GP70 ANTIGEN; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; P1A ANTIGEN; PRL1A ANTIGEN; PROSTAGLANDIN E2; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; CARCINOGENESIS; CELL INFILTRATION; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR IMMUNOLOGY;

HUMANS; IMMUNE TOLERANCE; NEOPLASMS; TUMOR ESCAPE;

EID: 0242427455     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.9.799478     Document Type: Review

References (252)

1. Ehrlich, P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909, 5: 273-90.
2. Medawar, P. The future of transplantation biology and medicine. Transplant Proc 1969, 1: 666-9.
3. Burnet, F.M. Cancer - A biological approach. Brit Med J 1957, 1: 841-7.
4. Burnet, F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13: 1-27.
5. Burnet, F.M. Immunological surveillance in neoplasia. Transplant Rev 1971, 7: 3-25.
6. Old, L.J., Boyse, E.A. Specific antigens of tumors and leukemias of experimental animals. Med Clin North Am 1966, 50: 901-12.
7. Old, L.J., Boyse, E.A. Prospects for immunotherapy of human cancer. Ann Intern Med 1968, 69: 393-7.
8. Klein, E., Klein, G. Tumour-associated antigens. Potential application in research, tumour therapy and tumour prevention. Triangle 1972, 11: 15-22.
9. Klein, G. Tumor associated immune reactions in cancer patients. Schweiz Med Wochenschr 1972, 102: 1163-5.
10. Flanagan, S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966, 8: 295-309.
11. Pantelouris, E.M. Absence of thymus in a mouse mutant. Nature 1968, 217: 370-1.
12. Stutman, O. Immunologic studies on resistance to oncogenic agents in mice. Natl Cancer Inst Monogr 1972, 35: 107-15.
13. Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183: 534-6.
14. Stutman, O. Immunodepression and malignancy. Adv Cancer Res 1975, 22: 261-422.
15. Stutman, O. Spontaneous tumors in nude mice: Effect of the viable yellow gene. Exp Cell Biol 1979, 47: 129-35.
16. Stutman, O. Chemical carcinogenesis in nude mice: Comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 1979, 62: 353-8.
17. Rygaard, J., Povlsen, C.O. Is immunological surveillance not a cell-mediated immune function? Transplantation 1974, 17: 135-6.
18. Rygaard, J., Povlsen, C.O. The nude mouse vs. the hypothesis of immunological surveillance. Transplant Rev 1976, 28: 43-61.
19. Rygaard, J., Povlsen, C.O. Immunological surveillance revisited. Tokai J Exp Clin Med 1983, 8: 529-32.
20. Herberman, R.B., Holden, H.T. Natural cell-mediated immunity. Adv Cancer Res 1978, 27: 305-77.
21. Dighe, A.S. et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1: 447-56.
22. Kaplan, D.H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95: 7556-61.
23. Street, S.E. et al. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97: 192-7.
24. Street, S.E. et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002, 196: 129-34.
25. Russell, J.H., Ley, T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20: 323-70.
26. Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68: 855-67.
27. Shankaran, V. et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410: 1107-11.
28. Dunn, G.P. et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002, 3: 991-8.
29. Penn, I. Post-transplant malignancy: The role of immunosuppression. Drug Saf 2000, 23: 101-13.
30. Penn, I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000, 7: 147-56.
31. Penn, I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998: 147-58.
32. Boshoff, C., Weiss, R. AIDS-related malignancies. Nat Rev Cancer 2002, 2: 373-82.
33. Penn, I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61: 274-8.
34. Otley, C.C., Pittelkow, M.R. Skin cancer in liver transplant recipients. Liver Transpl 2000, 6: 253-62.
35. Penn, I. Sarcomas in organ allograft recipients. Transplantation 1995, 60: 1485-91.
36. Pham, S.M. et al. Solid tumors after heart transplantation: Lethality of lung cancer. Ann Thorac Surg 1995, 60: 1623-6.
37. Chapman, J.R. et al. Recurrence of cancer after renal transplantation. Transplant Proc 2001, 33: 1830-1.
38. Birkeland, S.A. et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995, 60: 183-9.
39. Clark, W.H., Jr. et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81: 1893-1904.
40. Clemente, C.G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77: 1303-10.
41. Mihm, M.C., Jr. et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996, 74: 43-7.
42. Schumacher, K. et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001, 61: 3932-6.
43. Marrogi, A.J. et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997, 74: 492-501.
44. Vesalainen, S. et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of longterm prognosis in prostatic adenocarcinoma. Eur J Cancer 1994, 30A: 1797-803.
45. Halpern, A.C., Schuchter, L.M. Prognostic models in melanoma. Semin Oncol 1997, 24: S2-7.
46. Nakano, O. et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinico-pathologic demonstration of antitumor immunity. Cancer Res 2001, 61: 5132-6.
47. Naito, Y. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998, 58: 3491-4.
48. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348: 203-13.
49. Jaffee, E.M., Pardoll, D.M. Murine tumor antigens: Is it worth the search? Curr Opin Immunol 1996, 8: 622-7.
50. Klein, G. Rejection antigens in chemically induced tumors. Proc Natl Acad Sci USA 1997, 94: 5991-2.
51. Lethe, B. et al. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992, 22: 2283-8.
52. Boon, T. et al. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 1992, 13: 23-37.
53. Van den Eynde, B. et al. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991, 173: 1373-84.
54. Sibille, C. et al. Structure of the gene of tumtransplantation antigen P198: A point mutation generates a new antigenic peptide. J Exp Med 1990, 172: 35-45.
55. Szikora, J.P. et al. Structure of the gene of tumtransplantation antigen P35B: Presence of a point mutation in the antigenic allele. Embo J 1990, 9: 1041-50.
56. Van den Eynde, B. et al. Human tumour antigens recognized by T-cells: Perspectives for new cancer vaccines. Biochem Soc Trans 1995, 23: 681-6.
57. Kawakami, Y., Rosenberg, S.A. Human tumor antigens recognized by T-cells. Immunol Res 1997, 16: 313-39.
58. Gilboa, E. The makings of a tumor rejection antigen. Immunity 1999, 11: 263-70.
59. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10: 281-7.
60. Sahin, U. et al. Serological identification of human tumor antigens. Curr Opin Immunol 1997, 9: 709-16.
61. Old, L.J., Chen, Y.T. New paths in human cancer serology. J Exp Med 1998, 187: 1163-7.
62. Renkvist, N. et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001, 50: 3-15.
63. Boon, T., van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996, 183: 725-9.
64. Wang, R.F., Rosenberg, S.A. Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170: 85-100.
65. Hicklin, D.J. et al. Beta-2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998, 101: 2720-9.
66. Restifo, N.P. et al. Loss of functional beta-2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996, 88: 100-8.
67. Restifo, N.P. et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993, 177: 265-72.
68. Korkolopoulou, P. et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996, 73: 148-53.
69. Sanda, M.G. et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995, 87: 280-5.
70. Seliger, B. et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol 1997, 25: 608-14.
71. Ramal, L.M. et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000, 61: 1001-12.
72. Versteeg, R. et al. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 1989, 170: 621-35.
73. Soong, T.W., Hui, K.M. Locus-specific transcriptional control of HLA genes. J Immunol 1992, 149: 2008-20.
74. Koopman, L.A. et al. Human leukocyte antigen class I gene mutations in cervical cancer. J Natl Cancer Inst 1999, 91: 1669-77.
75. Marincola, F.M. et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 1994, 16: 13-23.
76. Johnsen, A.K. et al. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int J Cancer 2001, 91: 366-72.
77. De Baetselier, P. et al. Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature 1980, 288: 179-81.
78. Garrido, F. et al. Further evidence for depression of H-2 and la-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 1976, 261: 705-7.
79. Garrido, F. et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18: 89-95.
80. Zheng, P. et al. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: Lessons from recurrent tumors. Cancer Res 1999, 59: 3461-7.
81. Algarra, I. et al. Altered MHC class I antigens in tumors. Int J Clin Lab Res 1997, 27: 95-102.
82. Marincola, F.M. et al. HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol 1995, 18: 242-52.
83. Porgador, A. et al. Natural killer cell lines kill autologous beta-2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 1997, 94: 13140-5.
84. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285: 727-9.
85. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999, 96: 6879-84.
86. Garrido, F., Algarra, I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001, 83: 117-58.
87. Lopez-Botet, M. et al. NK cell recognition of non-classical HLA class I molecules. Semin Immunol 2000, 12: 109-19.
88. Carosella, E.D. et al. HLA-G: A tolerance molecule from the major histocompatibility complex. Immunol Today 1999, 20: 60-2.
89. Onno, M. et al. Modulation of HLA-G antigens expression by human cytomegalovirus: Specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol 2000, 164: 6426-34.
90. Lefebvre, S. et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002, 196: 266-74.
91. Urosevic, M. et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001, 159: 817-24.
92. Urosevic, M. et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002, 99: 609-17.
93. Urosevic, M. et al. HLA-G and its KIR ligands in cancer - Another enigma yet to be solved? J Pathol 2002, 196: 252-3.
94. De Vries, T.J. et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997, 57: 3223-9.
95. Hofbauer, G.F. et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution. Melanoma Res 1998, 8: 337-43.
96. Lee, K.H. et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998, 161: 4183-94.
97. Riker, A. et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999, 126: 112-20.
98. Jager, E. et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996, 66: 470-6.
99. Schreiber, H. et al. Immunodominance and tumor escape. Semin Cancer Biol 2002, 12: 25-31.
100. Miescher, S. et al. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 1988, 48: 6992-8.
101. Miescher, S. et al. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 1988, 42: 659-66.
102. Ochoa, A.C., Longo, D.L. Alteration of signal transduction in T cells from cancer patients. Important Adv Oncol 1995: 43-54.
103. Finke, J. et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999, 20: 158-60.
104. Whiteside, T.L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999, 48: 346-52.
105. Horiguchi, S. et al. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 1999, 59: 2950-6.
106. Irving, B.A., Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64: 891-901.
107. Finke, J.H. et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993, 53: 5613-6.
108. Zea, A.H. et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995, 1: 1327-35.
109. Kono, K. et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996, 2: 1825-8.
110. Nakagomi, H. et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53: 5610-2.
111. Lai, P. et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996, 2: 161-73.
112. Reichert, T.E. et al. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998, 58: 5344-7.
113. Kuss, I. et al. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999, 5: 329-34.
114. Rabinowich, H. et al. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996, 2: 1263-74.
115. Kono, K. et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996, 26: 1308-13.
116. Otsuji, M. et al. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996, 93: 13119-24.
117. Rabinowich, H. et al. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998, 101: 2579-88.
118. Saito, T. et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999, 5: 1263-73.
119. Gastman, B.R. et al. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 1999, 59: 1422-7.
120. Taheri, F. et al. L-arginine regulates the expression of the T-cell receptor zeta chain (CD3 zeta) in Jurkat cells. Clin Cancer Res 2001, 7: 958s-965s.
121. Rodriguez, P.C. et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002, 277: 21123-9.
122. Schmielau, J., Finn, O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001, 61: 4756-60.
123. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002, 195: 161-9.
124. Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001, 7: 94-100.
125. Straus, S.E. et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98: 194-200.
126. Muzio, M. et al. An induced proximity model for caspase-8 activation. J Biol Chem 1998, 273: 2926-30.
127. Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388: 190-5.
128. Medema, J.P. et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999, 190: 1033-8.
129. Landowski, T.H. et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90: 4266-70.
130. Gronbaek, K. et al. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity. Blood 1998, 92: 3018-24.
131. Shin, M.S. et al. Alterations of Fas(Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999, 154: 1785-91.
132. Shin, M.S. et al. Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer. Oncogene 2002, 21: 4129-36.
133. Shin, M.S. et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 2002, 99: 4094-9.
134. Pitti, R.M. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396: 699-703.
135. Hersey, P., Zhang, X.D. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001, 1: 142-50.
136. Niehans, G.A. et al. Human lung carcinomas express Fas ligand. Cancer Res 1997, 57: 1007-12.
137. Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996, 274: 1363-6.
138. O'Connell, J. et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184: 1075-82.
139. Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 1996, 2: 1361-6.
140. Restifo, N.P. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000, 6: 493-5.
141. Cappello, P. et al. Death receptor ligands in tumors. J Immunother 2002, 25: 1-15.
142. Marincola, F.M. et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996, 19: 266-77.
143. Toi, M. et al. Clinical significance of the determination of angiogenic factors. Eur J Cancer 1996, 32A: 2513-9.
144. Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998, 160: 1224-32.
145. Saito, H. et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998, 78: 1573-7.
146. Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6: 1755-66.
147. Girolomoni, G., Ricciardi-Castagnoli, P. Dendritic cells hold promise for immunotherapy. Immunol Today 1997, 18: 102-4.
148. Allavena, P. et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998, 28: 359-69.
149. De Smedt, T. et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997, 27: 1229-35.
150. Sharma, S. et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999, 163: 5020-8.
151. Ludewig, B. et al. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol 1995, 25: 1943-50.
152. Carbone, E. et al. Recognition of autologous dendritic cells by human NK cells. Eur J Immunol 1999, 29: 4022-9.
153. Yue, F.Y. et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997, 71: 630-7.
154. Salazar-Onfray, F. et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 1997, 159: 3195-202.
155. Zeidler, R. et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997, 90: 2390-7.
156. Ristimaki, A. et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997, 57: 1276-80.
157. Sano, H. et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55: 3785-9.
158. Wolff, H. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58: 4997-5001.
159. Huang, M. et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998, 58: 1208-16.
160. Gorsch, S.M. et al. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992, 52: 6949-52.
161. Doran, T. et al. Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J Immunother 1997, 20: 372-6.
162. Forgensen, J. Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2001, 5: 681.
163. Chen, W. et al. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001, 14: 715-25.
164. Matzinger, P. An innate sense of danger. Ann NY Acad Sci 2002, 961: 341-2.
165. Schwartz, R.H. A cell culture model for T lymphocyte clonal anergy. Science 1990, 248: 1349-56.
166. Kurts, C. et al. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997, 186: 239-45.
167. Devitt, A. et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998, 392: 505-9.
168. Chen, L. et al. Costimulation of Tcells for tumor immunity. Immunol Today 1993, 14: 483-6.
169. Allison, J.P. et al. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995, 7: 682-6.
170. Levitsky, H.I. et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996, 156: 3858-65.
171. Chen, L. et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994, 179: 523-32.
172. Steinman, R.M. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001, 68: 106-66.
173. Banchereau, J., Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392: 245-52.
174. Schreurs, M.W. et al. Dendritic cell-based vaccines: From mouse models to clinical cancer immunotherapy. Crit Rev Oncog 2000, 11: 1-17.
175. Timmerman, J.M., Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999, 50: 507-29.
176. Becker, Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993, 7: 187-91.
177. Zeid, N.A., Muller, H.K. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993, 25: 338-43.
178. Furihata, M. et al. HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma - their distribution in relation to prognosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1992, 61: 409-14.
179. Tsujitani, S. et al. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990, 66: 2012-6.
180. Giannini, A. et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991, 187: 496-502.
181. Ambe, K. et al. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989, 63: 496-503.
182. Inoshima, N. et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 2002, 8: 3480-6.
183. Suzuki, A. et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 2002, 196: 37-43.
184. Murphy, G.F. et al. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: Relevance to immunologic regression and immunotherapy. J Invest Dermatol 1993, 100: 335S-341S.
185. Albert, M.L. et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392: 86-9.
186. Hoffmann, T.K. et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000, 60: 3542-9.
187. Gabrilovich, D.I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2: 1096-103.
188. Enk, A.H. et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997, 73: 309-16.
189. Gabrilovich, D.I. et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997, 3: 483-90.
190. Sakaguchi, S. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182: 18-32.
191. Sutmuller, R.P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194: 823-32.
192. Shimizu, J. et al. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999, 163: 5211-8.
193. Awwad, M., North, R.J. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989, 49: 1649-54.
194. Awwad, M., North, R.J. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res 1990, 50: 2228-33.
195. Rakhmilevich, A.L. et al. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int J Cancer 1993, 55: 338-43.
196. North, R.J., Dye, E.S. Ly 1 + 2-suppressor T cells down-regulate the generation of Ly 1-2 + effector T cells during progressive growth of the P815 mastocytoma. Immunology 1985, 54: 47-56.
197. Awwad, M., North, R.J. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2 + T cell-mediated immunity. J Exp Med 1988, 168: 2193-206.
198. Drebin, J.A. et al. Regulation of the immune response to antigens on the malignant cell surface. Springer Semin Immunopathol 1982, 5: 175-92.
199. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59: 3128-33.
200. Woo, E.Y. et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61: 4766-72.
201. Liyanage, U.K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169: 2756-61.
202. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411: 380-4.
203. Antony, P.A., Restifo, N.P. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 2002, 25: 202-6.
204. Park, S.H. et al. The contribution of NKT cells, NK cells and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 2003, 170: 1197-1201.
205. Bendelac, A. Mouse NK1+ T cells. Curr Opin Immunol 1995, 7: 367-74.
206. Bendelac, A. et al. Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu Rev Immunol 1997, 15: 535-62.
207. Cui, J. et al. Requirement for Valpha 14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278: 1623-6.
208. Hashimoto, W. et al. Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995, 154: 4333-40.
209. Kobayashi, E. et al. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995, 7: 529-34.
210. Motoki, K. et al. Antitumor activities of combined treatment with a novel immunomodulator (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3, 4-octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice. Oncol Res 1996, 8: 155-62.
211. Moodycliffe, A.M. et al. Immune suppression and skin cancer development: Regulation by NKT cells. Nat Immunol 2000, 1: 521-5.
212. Wang, Y. et al. Direct thymic involvement in anterior chamber-associated immune deviation: Evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice. J Immunol 1997, 158: 2150-5.
213. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000, 1: 515-20.
214. Bottazzi, B. et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983, 220: 210-2.
215. Zachariae, C.O. et al. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 1990, 171: 2177-82.
216. Van Damme, J. et al. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992, 176: 59-65.
217. Negus, R.P. et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995, 95: 2391-6.
218. Negus, R.P. et al. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997, 150: 1723-34.
219. Mazzucchelli, L. et al. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 1996, 149: 501-9.
220. Mantovani, A. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest 1994, 71: 5-16.
221. Huang, S. et al. Expression of the JE/MCP-1 gene suppresses metastatic
222. Sozzani, S. et al. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 1998, 92: 4036-9.
223. Miyamoto, M. et al. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother 1998, 47: 47-57.
224. Le, X. et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000, 20: 935-46.
225. Norgauer, J. et al. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol 1996, 156: 1132-7.
226. Wolf, J.S. et al. IL (interleukin)-1-alpha promotes nuclear factor-kappa-B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001, 7: 1812-20.
227. Maione, T.E. et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247: 77-9.
228. Wakabayashi, H. et al. Purification and identification of mouse lung microvessel endothelial cell-derived chemoattractant for lung-metastasizing murine RAW117 large-cell lymphoma cells: Identification as mouse monocyte chemotactic protein 1. Cancer Res 1995, 55: 4458-64.
229. Angiolillo, A.L. et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995, 182: 155-62.
230. Arenberg, D.A. et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997, 62: 554-62.
231. Moore, B.B. et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999, 154: 1503-12.
232. Bussolino, F. et al. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997, 22: 251-6.
233. Mantovani, A. et al. Cytokine regulation of endothelial cell function: From molecular level to the bedside. Immunol Today 1997, 18: 231-40.
234. Ueno, T. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6: 3282-9.
235. Goede, V. et al. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999, 82: 765-70.
236. Salcedo, R. et al. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96: 34-40.
237. Leek, R.D. et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002, 62: 1326-9.
238. Brigati, C. et al. Tumors and inflammatory infiltrates: Friends or foes? Clin Exp Metastasis 2002, 19: 247-58.
239. Tsung, K. et al. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002, 62: 5069-75.
240. Balkwill, F., Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357: 539-45.
241. Schoppmann, S.F. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161: 947-56.
242. Mantovani, A. et al. The origin and function of tumor-associated macrophages. Immunol Today 1992, 13: 265-70.
243. Johnsen, M. et al. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998, 10: 667-71.
244. Blasi, F. Proteolysis, cell adhesion, chemotaxis and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999, 82: 298-304.
245. Opdenakker, G., Van Damme, J. Chemotactic factors, passive invasion and metastasis of cancer cells. Immunol Today 1992, 13: 463-4.
246. Nakashima, E. et al. Human MCAFgene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res 1995, 12: 1598-1604.
247. Rollins, B.J., Sunday, M.E. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991, 11: 3125-31.
248. Hirose, K. et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 1995, 72: 708-14.
249. Manome, Y. et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: An effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 1995, 41: 227-35.
250. Zhang, L. et al. Antibody to Mac-1 or monocyte chemoattractant protein-1 inhibits monocyte recruitment and promotes tumor growth. J Immunol 1997, 158: 4855-61.
251. Tonouchi, H. et al. Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Scand J Gastroenterol 2002, 37: 830-3.
252. Nesbit, M. et al. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001, 166: 6483-90.